Pharmaceutical Intermediates
- • Analgesics (56)
- • Anesthetics (52)
- • Anti-Addiction Agents (8)
- • Antibacterials (117)
- • Anticonvulsants (20)
- • Antidementia Agents (23)
- • Antidepressants (35)
- • Antiemetics (24)
- • Antifungals (24)
- • Antigout Agents (9)
- • Anti-inflammatory Agents (28)
- • Antimigraine Agents (21)
- • Antineoplastics (425)
- • Antiparasitics (11)
- • Antiparkinson Agents (28)
- • Antipsychotics (54)
- • Antispasticity Agents (12)
- • Antivirals (146)
- • Anxiolytics (16)
- • Blood Glucose Regulators (105)
- • Blood Products (61)
- • Cardiovascular Agents (179)
- • CNS Agents (22)
- • Dental and Oral Agents (8)
- • Dermatological Agents (19)
- • Electrolytes (15)
- • Gastrointestinal Agents (62)
- • Genetic/Enzyme Disorder (12)
- • Genitourinary Agents (47)
- • Immunological Agents (36)
- • Metabolic Bone Disease (6)
- • Ophthalmic Agents (32)
- • Respiratory Tract (51)
- • Skeletal Muscle Relaxants (5)
- • Sleep Disorder Agents (28)
- • Oled Material Intermediate (333)
- • Heterocyclic Compound (9758)
- • Bulk Drug Intermediates (17690)
Related News
-
Iran's Only MDI/TDI Plant Attacked, Middle East Supply Nearly Zero, Global Gap Widens
2026-06-10 -
ICIS Global No.58: ECHEMI Again Ranks Among the World’s Chemical Distributors
2026-06-16 -
Iran Closes Strait of Hormuz to All Vessels: Global Chemical Trade Gets Choked
2026-06-11 -
Hormuz Reopening Signal: 155 Tankers Still Waiting
2026-06-16 -
Hormuz Is Reopening, But Chemical Logistics May Take Months to Recover
2026-06-22 -
Wanhua Resumes PO Production: How Much Can Polyether Producers Save on Costs?
2026-06-12
Metabolic Bone Disease
3-Pyridineacetic acid, hydrochloride (1:1)
(6419-36-9)-
Pharmaceutical Grade / 99%
-
Pharmaceutical Grade / 99%
-
Industrial Grade / pharmaceutical grade / 99%
-
pharmaceutical grade / 98%
Request for quotation , get quotes from more suppliers.
3-Pyridineacetic acid
(501-81-5)-
Pharmaceutical Grade / 99%
-
Industrial Grade / 99%
-
-
Request for quotation , get quotes from more suppliers.
More Information
Metabolic Bone Disease Pharma Intermediates are essential raw materials used in the synthesis of therapeutics targeting bone metabolism disorders. These intermediates provide the foundation for osteoporosis treatments, vitamin D analogues, calcium regulators, and bone resorption modulators.
Common applications and types include:
• Vitamin D and analog intermediates — for promoting bone mineralization and treating rickets or osteomalacia.
• Calcium and phosphate regulators — supporting drugs that maintain proper mineral balance.
• Bisphosphonate intermediates — used to inhibit bone resorption in osteoporosis and Paget’s disease.
• Parathyroid hormone (PTH) intermediates — for managing calcium homeostasis and bone formation.
Frequently Asked Questions
Metabolic Bone Disease (MBD) refers to a group of disorders characterized by abnormalities in bone strength, structure, or mineralization due to disturbances in calcium, phosphorus, vitamin D metabolism, or hormonal regulation. Common types include osteoporosis, osteomalacia, rickets, and Paget’s disease. These conditions can lead to increased fracture risk, bone pain, and skeletal deformities if left untreated.
Common causes of Metabolic Bone Disease include vitamin D deficiency, inadequate calcium intake, chronic kidney disease, hyperparathyroidism, hormonal imbalances (such as low estrogen or testosterone), and certain medications like glucocorticoids. Lifestyle factors such as sedentary behavior, smoking, and excessive alcohol consumption can also contribute to the development of MBD.
Diagnosis of Metabolic Bone Disease typically involves a combination of clinical evaluation, blood tests (to assess calcium, phosphorus, alkaline phosphatase, vitamin D, and parathyroid hormone levels), imaging studies like dual-energy X-ray absorptiometry (DXA) scans for bone mineral density, and sometimes bone biopsies. Early diagnosis is crucial to prevent complications such as fractures and progressive bone loss.
Treatment for Metabolic Bone Disease depends on the underlying cause but often includes nutritional supplementation (e.g., calcium and vitamin D), lifestyle modifications (weight-bearing exercise, smoking cessation), and medications such as bisphosphonates, denosumab, teriparatide, or hormone replacement therapy. In cases related to kidney disease or endocrine disorders, managing the primary condition is essential for effective bone health restoration.
Yes, many forms of Metabolic Bone Disease can be prevented through adequate intake of calcium and vitamin D, regular weight-bearing physical activity, avoiding tobacco and excessive alcohol, and routine bone density screening—especially for high-risk groups such as postmenopausal women and older adults. Early intervention and management of underlying medical conditions also play a key role in prevention.